Navigation Links
Nile Therapeutics Reports 2010 Third Quarter Financial Results
Date:11/12/2010

significant blood pressure reduction at 5 ng/kg/min.  

Secondary and exploratory analyses at doses of 1.25 and 2.5 ng/kg/min demonstrated favorable effects of CD-NP on renal function, as compared to placebo. At these doses, CD-NP appeared to have favorable trends in biomarkers that are correlated with kidney function, including creatinine and cystatin-c. Data will be presented at an upcoming cardiology conference.

About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. This hospitalization rate is almost double the rate seen 15 years ago, and is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $33 billion.

About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timeli
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
(Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... 4, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... in Phoenix, Arizona on Thursday, November 11, 2010 at 5:30 ... Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
... N.C., Nov. 4, 2010 Gentris Corporation ( ... pharmacogenomics, announced today that Howard McLeod, Pharm.D., from ... (UNC) has become the Company,s first Chief Scientific ... pharmacogenomics and personalized medicine, is the Fred N. ...
Cached Medicine Technology:Gentris Corporation Names New Chief Scientific Advisor 2Gentris Corporation Names New Chief Scientific Advisor 3
(Date:7/31/2015)... , ... July 31, 2015 , ... “ Crack’em ” ... latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert and ... helps chefs make less mess while cooking. , Cooking can be a very messy ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Super-Sod wants ... with a Super-Sod Pro Page as the perfect fit for such a ... pictures and articles. The social website is a dynamic site that spreads home and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products ... of nutritional and wellness products, announced the addition of Vincent Aquilino to its ... active isolated stretching and the prevention and rehabilitation of injuries, has spent the ...
(Date:7/31/2015)... ... , ... Easter Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, ... AM. The duathlon is a 2 mile run, 13 mile bike ride, and a 3 ... mile bike, and a 3 mile run. Heels & Wheels is sponsored by Mayo ...
Breaking Medicine News(10 mins):Health News:Make Less Mess while Cooking with Crack’em 2Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2
... , MONDAY, Dec. 5 (HealthDay News) -- When people with ... a third worrisome condition -- dementia -- goes up ... 2 diabetes are twice as likely to develop dementia three ... nondepressed people with diabetes, researchers found. "We,ve known for ...
... Calif. -- Aspirin taken within five days of cardiac ... risk of major postoperative complications, including renal failure, a ... (30-day mortality), according to a study by researchers at ... to appear in the journal Annals of Surgery ...
... been launched to help raise awareness of work being done ... childhood obesity and to seek the views of parents and ... of childhood overweight and obesity, led by a team of ... One-quarter of babies gain weight more rapidly than they should ...
... HealthDay Reporter , MONDAY, Dec. 5 (HealthDay News) -- ... using a preventive medication, according to new research. That ... the late 1980s. Preventive asthma medications help control ... the U.S. National Asthma Education and Prevention Program recommend their ...
... available in German . , The extent ... depends on motivation and will power or the physical condition ... latter particularly leads to noticeable and measurable performance impairments. For ... confined to changes in the muscle itself. Now, a joint ...
... 4 (HealthDay News) -- Variations in genes involved in ... disorder (ADHD), according to a new study. The ... may offer a new treatment option for ADHD patients ... researchers said. In the study, researchers conducted whole-genome ...
Cached Medicine News:Health News:Risk for Dementia Rises When Diabetes, Depression Meet: Study 2Health News:Risk for Dementia Rises When Diabetes, Depression Meet: Study 3Health News:Preoperative aspirin therapy can benefit cardiac surgery patients 2Health News:Parents' views sought on childhood obesity risk 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:How muscle fatigue originates in the head 2Health News:More Evidence Links Specific Genes to ADHD 2
... enhances productivity in the laboratory with its ... methods clotting, chromogenic and immunological ... test results every time. With user ... random access, the CA-1500 will provide you ...
... Premier is our top-of-the-line device. ... attributes of the Qwik-Let® Elite, ... Lan-X feature. The Lan-X technology ... protection in the removal and ...
... the pain and hassle of testing. Unlike ... device is the only one with a ... testing, with less hassle and improved safety. ... and no side-to-side motion for less skin ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: